Latest From Synedgen Inc.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2016.
- Medical Devices
- Therapeutic Areas
- Dental & Oral Products
- Musculoskeletal & Connective Tissue Disorders
- Respiratory, Pulmonary
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Synedgen Inc.
- Senior Management
WIllaim Weismann, MD, CEO
Shenda Baker, PhD, Pres, COO & Treas.urer
Stacy Townsend, PhD, VP, Rsch.
- Contact Info
Phone: (909) 447-6858
1420 N. Claremont Blvd., Ste. 105D
Claremont, CA 91711
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.